Hypericin and its anticancer effects: From mechanism of action to potential therapeutic application

• Published in: Phytomedicine (Stuttgart) 2022-10, Vol.105, p.154356-154356, Article 154356
• Main Authors: Choudhary, Neeraj, Collignon, Taylor E., Tewari, Devesh, Bishayee, Anupam
• Format: Article
• Language: English
• Subjects: Anticancer potential; Hypericin; Molecular targets; Safety profile; Therapeutics
• ISSN: 0944-7113; 1618-095X
• DOI: 10.1016/j.phymed.2022.154356

Emerging studies indicate that hypericin has diverse pharmacological actions and exhibits potential for treatment of various types of cancer. The current review evaluates the pharmacological activity, associated molecular mechanism, and therapeutic application of hypericin as an anticancer agent according to the most recent state of knowledge with special emphasis on clinical trials and safety profile. This review follows The Preferred Reporting Items for Systematic Reviews criteria. Various databases, including PubMed, Scopus and Science Direct, were used to search and collect relevant literature. The major keywords used included the following: cancer, distribution, property, signaling pathway, pharmacological effect, treatment, prevention, in vitro and in vivo studies, toxicity, bioavailability, and clinical trials. One hundred three articles met the established inclusion and exclusion criteria. Hypericin has shown anticancer activity against the expansion of several cell types including breast cancer, cervical cancer, colorectal cancer, colon cancer, hepatocellular carcinoma, stomach carcinoma, leukemia, lung cancer, melanoma, and glioblastoma cancer. Hypericin exerts its anticancer activity by inhibiting pro-inflammatory mediators, endothelial growth factor, fibroblast growth factor, cell adhesion, angiogenesis, and mitochondrial thioredoxin. It has also been shown to cause an increase in the levels of caspase-3 and caspase-4, arrest the cell cycle at metaphase leading to cancer cell apoptosis, and affect various protein and gene expression patterns. Hypericin exhibits significant inhibitory activity against various types of in vitro and in vivo cancer models. However, well-designed, high quality, large-scale and multi-center randomized clinical studies are required to establish the safety and clinical utility of hypericin in cancer patients. [Display omitted]